Resumen de CAR‑T cell therapy: a game‑changer in cancer treatment and beyond
Kumar Utkarsh, Namita Srivastava, Sachin Kumar, Azhar Z. Khan, Gunjan Dagar, Mayank Singh, Mukesh Kumar, Shabirul Haque
In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modifcation of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a signifcant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing eforts to develop additional CAR constructs such as bispecifc CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.
